Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS)
LEADS is a study of early onset Alzheimer’s Disease (EOAD), conducted at research hubs and clinical sites across the United States. The LEADS study aims to collect clinical, genetic, and biomarker data on early-onset Alzheimer's disease (EOAD), explore its unique features, develop sensitive clinical trial measures, and establish a network of sites for future trials. Participants are recruited from the clinics or longitudinal research cohorts at each study site across the United States of America. Recruitment is still ongoing however since 2018, baseline assessment has been completed for over 300 participants. The study plans to enroll over 700 participants with and without EOAD who are between the age of 40 and 64 years as well as a study partner for each participant. Participants will be followed up annually.
Study design
Cohort
Number of participants at first data collection
349 (participants)
Recruitment is ongoing
Age at first data collection
40 - 64 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Country
Year of first data collection
2018
Primary Institutions
Indiana University School of Medicine (IU School of Medicine)
Links
clinicaltrials.gov/study/NCT03507257
alzheimers.gov/clinical-trials/longitudinal-early-onset-alzheimers-disease-study-leads
Profile paper DOI
Funders
Alzheimer's Association
Alzheimer's Therapeutic Research Institute (ATRI)
Ongoing?
Yes
Data types collected
- Audio or visual recordings (e.g. of child behaviour, facial expressions)
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – face-to-face
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- None
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- None
Engagement
Keywords
